The Department of Defense's Defense Health Agency awarded a $4,239,889 Project Grant to Enteralia Bioscience LLC on July 1, 2024 through the Military Medical Research and Development program (CFDA 12.420). The grant supports the development of an oral enzymatic therapy as an adjunctive treatment to the dietary management of celiac disease. The research project aims to transform health care for service members and the American public through innovative biomedical research, with a focus on investigating medical solutions for the battlefield. The 3-year grant period runs from July 1, 2024 to June 30, 2027.
Generated 2/25/25, 5:35 AM